Maria Rosario Pac-Sa

Dr. Maria Rosario Pac-Sa


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
PVPaula Vidal-Utrillas
Paula Vidal-Utrillas
MLMarta Latorre-Poveda
Marta Latorre-Poveda
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
In October 2020, we conducted a population-based prospective cohort study to determine post-COVID-19 complications, recovery, return to usual health, and associated risk factors in 536 cases of COVID-19 outbreak in Borriana (Spain) by administering an epidemiological questionnaire via phone interviews. A total of 484 patients participated (90.3%), age mean 37.2 ± 17.1 years, and 301 females (62.2%). Mild illness was the most common COVID-19 manifestation. After six months, 160 patients (33.1%) suffered at least one complication post-COVID-19, and 47 (29.4%) of them sought medical assistance. The most frequent persistent symptoms were hair loss, fatigue, loss of smell or taste, and headache. Risk factors associated with a complication were female sex (adjusted relative risk, [aRR] = 1.93 95% confidence interval [CI] 1.41–2.65), age 35 years and above (aRR = 1.50 95% CI 1.14–1.99), B blood group (aRR = 1.51 95% CI 1.04–2.16), current smoker (RR = 1.61 95% CI 1.02–2.54), and at least a COVID-19 exposure (aRR = 2.13 95% CI 1.11–4.09). Male sex, age younger than 35 years, and low COVID-19 exposures were associated with better recovery and return to usual health. A third of patients presented persistent symptoms compatible with the long-COVID-19 syndrome. In conclusion, an active medical follow-up of post-COVID-19 patients must be implemented.

SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
PVPaula Vidal-Utrillas
Paula Vidal-Utrillas
MLMarta Latorre-Poveda
Marta Latorre-Poveda
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
After a COVID-19 outbreak in the Falles festival of Borriana (Spain) during March 2020, a cohort of patients were followed until October 2020 to estimate complications post-COVID-19, considering ABO blood groups (ABO). From 536 laboratory-confirmed cases, 483 completed the study (90.1%) carried by the Public Health Center of Castelló and the Emergency and Microbiology and Clinical Analysis of Hospital de la Plana Vila-real. The study included ABO determination and telephone interviews of patients. The participants had a mean age of 37.2 ± 17.1 years, 300 females (62.1%). ABO were O (41.4%), A (45.5%), B (9.1%), and AB (3.9%). We found no difference in the incidence of COVID-19 infections. A total of 159 (32.9%) patients reported one or more post-COVID-19 complications with divergent incidences after adjustment: O (32.3%), A (32.6%), B (54.1%), and AB (27.6%); B groups had more complications post-COVID-19 when compared with O group (adjusted relative risk [aRR] 95% confidence interval [CI] 1.68, 95% CI 1.24–2.27), and symptoms of fatigue (1.79, 95% CI 1.08–2.95), myalgia (2.06, 95% CI 1.10–3.84), headache (2.61, 95% CI 1.58–4.31), and disorder of vision (4.26 95% CI 1.33–13.60). In conclusion, we observed significant differences in post-COVID-19 complications by ABO, with a higher incidence in B group. Additional research is justified to confirm our results.

12 October 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
GBGema Badenes-Marques
Gema Badenes-Marques
MFMARIA GIL FORTUÑO
MARIA GIL FORTUÑO
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Background: In March 2020, a COVID-19 outbreak linked to mass gathering dinners at the Falles Festival in Borriana, Spain, resulted in an estimated attack rate of 42.6% among attendees. Methods: In June 2022, we conducted a cross-sectional follow-up study of 473 adults aged 18 to 64 who attended the dinners at the Falles Festival in 2020, examining the cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, infection records, and vaccinations from a population-based vaccine registry. Blood samples were analyzed for SARS-CoV-2 antibodies and cellular immunity. We employed a doubly robust inverse-probability weighting analysis to estimate the booster vaccine dose’s impact on long COVID prevalence and symptom count. Results: A total of 28.1% of participants met the WHO criteria for long COVID, with older individuals showing higher rates. Long COVID diagnosis was less likely with factors including O blood group, higher occupational status, physical activity, three vaccine doses, strong SARS-CoV-2-S-reactive IFNγ-producing-CD8+ response, and infection during the Omicron period. Increased age, high or low social activity, underlying health conditions, a severe initial COVID episode, and reinfection were associated with higher long COVID likelihood. A booster dose, compared to one or two doses, reduced long COVID risk by 74% (95% CI: 56% to 92%) and symptom count by 55% (95% CI: 32% to 79%). Conclusion: Long COVID was prevalent in a significant portion of those who contracted COVID-19, underscoring the need for sustained follow-up and therapeutic strategies. Vaccinations, notably the booster dose, had a substantial beneficial effect on long-term infection outcomes, affirming the vaccination’s role in mitigating SARS-CoV-2 infection consequences.

28 January 2023 in Epidemiologia
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
OGOlga Guerra-Murcia
Olga Guerra-Murcia
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Our objective was to estimate the incidence of COVID-19 and the ABO blood Groups in the mass-gathering events (MGEs) during the Falles Festival in Borriana (Spain) from 6–10 March 2020. We conducted a population-based retrospective cohort study and measured anti-SARS-CoV-2 antibodies and the ABO of participants. We performed laboratory COVID-19 tests and obtained the ABO in 775 subjects (72.8% of the original exposed cohort): O-group (45.2%), A-group (43.1%), B-group (8.5%) and AB-group (3.4%). Adjusted for confounding factors, including COVID-19 exposure during the MGEs, attack rates of COVID-19 for each ABO group were 55.4%, 59.6%, 60.2%, and 63.7%. The adjusted relative risks were for O-group 0.93 (95% Confidence Interval [CI] 0.83–1.04), for A-group 1.06 (95% CI 0.94–1.18), for B-group 1.04 (95%CI 0.88–1.24), and for AB-group 1.11 (95% CI 0.81–1.51) with no significant differences. Conclusions: Our results suggest no effect of ABO on COVID-19 incidence. We observed weak but not significant protection of the O-group and not a significantly greater infection risk for the remaining groups compared with the O-group. More studies are needed to resolve the controversies regarding the association between ABO and COVID-19.

30 June 2021 in COVID
Verified
Journal Article
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
MPMaria Rosario Pac-Sa
Maria Rosario Pac-Sa
PVPaula Vidal-Utrillas
Paula Vidal-Utrillas
MLMarta Latorre-Poveda
Marta Latorre-Poveda
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
In March 2020, several mass gathering events were related to the Falles festival in Borriana (Spain), resulting in a 536 laboratory-confirmed COVID-19 cases outbreak among participants. This article estimates anti-SARS-CoV-2 antibodies persistence six months after and factors associated with antibody response. A prospective population-based cohort study was carried out by the Public Health Centre of Castellon and the Emergency and Clinical Analysis and Microbiology Services of Hospital de la Plana in Vila-real. In October 2020, a seroepidemiologic study was used to estimate the persistence of anti-SARS-CoV-2 antibodies against nucleocapsid protein (N) by an electrochemiluminescence immunoassay (ECLIA) was implemented. We enrolled 484 (90.2%) of the 536 members of the initial outbreak cohort and detected persistent antibodies in 479 (99%) without reinfection episodes. Five participants had a negative antibody test. Factors associated with a negative result were a lower body mass index (BMI), and less contact with other COVID-19 cases. Among the 469 participants with two ECLIA tests, 96 (20.5%) had an increase of antibodies and 373 (79.5%) a decline. Increased antibodies were associated with older age, higher BMI, more severe illness, and low current smokers. Our results show that after a COVID-19 infection, a high proportion of cases maintain detectable anti-SARS-CoV-2 antibodies.

1 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
SDSalvador Domènech-Montoliu
Salvador Domènech-Montoliu
Joan Puig-BarberaJoan Puig-Barbera
Joan Puig-Barbera
GBGemma Badenes-Marques
Gemma Badenes-Marques
MFMARIA GIL FORTUÑO
MARIA GIL FORTUÑO
AOAlejandro Orrico-Sánchez
Alejandro Orrico-Sánchez
Alberto Arnedo-PenaAlberto Arnedo-Pena
Alberto Arnedo-Pena
Background: In March 2020, a COVID-19 outbreak associated with the Falles Festival in Borriana, Spain, led to significant infections. Methods: In June 2022, we conducted a cross-sectional follow-up study of 473 socially engaged adults aged 18 to 64, examining the cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, infection records, and vaccinations from a population-based vaccine registry. Blood samples were analyzed for SARS-CoV-2 antibodies and cellular immunity. We employed a doubly robust inverse weighted probability analysis to estimate the booster vaccine dose's impact on long COVID prevalence and symptom count. Results: 28.1% of participants met the WHO criteria for long COVID, with older individuals showing higher rates. Not complying with long COVID criteria associated with factors including O blood group, higher occupational status, physical activity, three vaccine doses, strong SARS-CoV-2-S-reactive IFNγ‐producing‐CD8+ response, and infection during the Omicron period. Conversely, increased age, high or low social activity, underlying health conditions, a severe initial COVID episode, and reinfection associated with higher long COVID likelihood. A booster dose, compared to one or two doses, reduced long COVID risk by 74% (95% CI: 56.4% to 91.7%) and symptom count by 55.2% (95% CI: 31.6% to 78.7%). Conclusion: Long COVID was prevalent in a significant portion of those who contracted COVID-19, underscoring the need for sustained follow-up and therapeutic strategies. Vaccinations, notably the booster dose, had a substantial beneficial effect on long-term infection outcomes, affirming the vaccination’s role in mitigating SARS-CoV-2 infection consequences.